Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1

Conditions

Recurrence 1Multiple Myeloma 1Advanced Solid Tumors 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × Dosage Forms × Clear all
NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed
61 enrolled 28 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT00632424 2016-03-10

Phase 1 Trial of Oral Ixabepilone

R-Pharm

Phase 1 Terminated
23 enrolled 11 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡